The FDA has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta.
Mother-to-child HBV transmission was effectively prevented by earlier initiation of TDF prophylaxis in pregnancy combined with HBV vaccination at birth for infants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback